scispace - formally typeset
L

Luisa Imberti

Researcher at Canadian Real Estate Association

Publications -  163
Citations -  8354

Luisa Imberti is an academic researcher from Canadian Real Estate Association. The author has contributed to research in topics: T cell & Medicine. The author has an hindex of 30, co-authored 141 publications receiving 5215 citations.

Papers
More filters
Journal ArticleDOI

Autoantibodies against type I IFNs in patients with life-threatening COVID-19.

Paul Bastard, +140 more
- 23 Oct 2020 - 
TL;DR: A means by which individuals at highest risk of life-threatening COVID-19 can be identified is identified, and the hypothesis that neutralizing auto-Abs against type I IFNs may underlie critical CO VID-19 is tested.
Journal ArticleDOI

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

Qian Zhang, +172 more
- 23 Oct 2020 - 
TL;DR: The COVID Human Genetic Effort established to test the general hypothesis that life-threatening COVID-19 in some or most patients may be caused by monogenic inborn errors of immunity to SARS-CoV-2 with incomplete or complete penetrance finds an enrichment in variants predicted to be loss-of-function (pLOF), with a minor allele frequency <0.001.
Journal ArticleDOI

Partial V(D)J Recombination Activity Leads to Omenn Syndrome

TL;DR: It is reported here that patients with Omenn syndrome, a severe immunodeficiency characterized by the presence of activated, anergic, oligoclonal T cells, hypereosinophilia, and high IgE levels, bear missense mutations in either the Rag-1 or Rag-2 genes that result in partial activity of the two proteins.
Journal ArticleDOI

Autoantibodies neutralizing type I IFNs are present in ~ 4% of uninfected individuals over 70 years old and account for ~ 20% of COVID-19 deaths.

Paul Bastard, +58 more
- 19 Aug 2021 - 
TL;DR: In this paper, the authors found that auto-antibodies neutralizing high concentrations (10 ng/mL, in plasma diluted 1 to 10) of IFN-α and/or -ω are found in about 10% of patients with critical COVID-19 pneumonia, but not in subjects with asymptomatic infections.